{"name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","slug":"istituto-romagnolo-per-lo-studio-dei-tumori-dino-amadori-irst-s-r-l-irccs","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"177Lu-PSMA","genericName":"177Lu-PSMA","slug":"177lu-psma","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_2"},{"name":"Anti-CD22 Immunotoxin","genericName":"Anti-CD22 Immunotoxin","slug":"anti-cd22-immunotoxin","indication":"B-cell lymphomas (CD22-positive)","status":"phase_2"},{"name":"Arm A: FOLFIRI or FOLFOX + Bevacizumab","genericName":"Arm A: FOLFIRI or FOLFOX + Bevacizumab","slug":"arm-a-folfiri-or-folfox-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Arm B: FOLFIRI or FOLFOX","genericName":"Arm B: FOLFIRI or FOLFOX","slug":"arm-b-folfiri-or-folfox","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Arm D: FOLFIRI or FOLFOX plus CETUXIMAB","genericName":"Arm D: FOLFIRI or FOLFOX plus CETUXIMAB","slug":"arm-d-folfiri-or-folfox-plus-cetuximab","indication":"Metastatic colorectal cancer, KRAS wild-type","status":"phase_3"},{"name":"Autologous DC vaccine","genericName":"Autologous DC vaccine","slug":"autologous-dc-vaccine","indication":"Melanoma","status":"phase_2"},{"name":"High intensity therapies","genericName":"High intensity therapies","slug":"high-intensity-therapies","indication":"Cancer (specific indication not specified in available data)","status":"phase_3"},{"name":"IL2","genericName":"IL2","slug":"il2","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Low intensity therapies","genericName":"Low intensity therapies","slug":"low-intensity-therapies","indication":"Cancer treatment in elderly or frail patients","status":"phase_3"}]}],"pipeline":[{"name":"177Lu-PSMA","genericName":"177Lu-PSMA","slug":"177lu-psma","phase":"phase_2","mechanism":"177Lu-PSMA is a radioligand therapy that delivers lutetium-177, a beta-emitting radioisotope, directly to prostate-specific membrane antigen (PSMA) on cancer cells, causing targeted cell death.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"Anti-CD22 Immunotoxin","genericName":"Anti-CD22 Immunotoxin","slug":"anti-cd22-immunotoxin","phase":"phase_2","mechanism":"An immunotoxin that binds to CD22 on B-cell lymphomas and delivers a cytotoxic payload to kill malignant cells.","indications":["B-cell lymphomas (CD22-positive)","Acute lymphoblastic leukemia (ALL, CD22-positive)"],"catalyst":""},{"name":"Arm A: FOLFIRI or FOLFOX + Bevacizumab","genericName":"Arm A: FOLFIRI or FOLFOX + Bevacizumab","slug":"arm-a-folfiri-or-folfox-bevacizumab","phase":"phase_3","mechanism":"FOLFIRI or FOLFOX chemotherapy regimens combined with bevacizumab inhibit tumor cell division and angiogenesis to treat colorectal cancer.","indications":["Metastatic colorectal cancer","Advanced colorectal cancer"],"catalyst":""},{"name":"Arm B: FOLFIRI or FOLFOX","genericName":"Arm B: FOLFIRI or FOLFOX","slug":"arm-b-folfiri-or-folfox","phase":"phase_3","mechanism":"FOLFIRI and FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluorouracil-based cytotoxic activity, with irinotecan targeting topoisomerase I or oxaliplatin targeting DNA cross-linking.","indications":["Metastatic colorectal cancer","Adjuvant treatment of stage III colorectal cancer"],"catalyst":""},{"name":"Arm D: FOLFIRI or FOLFOX plus CETUXIMAB","genericName":"Arm D: FOLFIRI or FOLFOX plus CETUXIMAB","slug":"arm-d-folfiri-or-folfox-plus-cetuximab","phase":"phase_3","mechanism":"This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth.","indications":["Metastatic colorectal cancer, KRAS wild-type","Advanced colorectal cancer"],"catalyst":""},{"name":"Autologous DC vaccine","genericName":"Autologous DC vaccine","slug":"autologous-dc-vaccine","phase":"phase_2","mechanism":"Stimulates an immune response against cancer cells","indications":["Melanoma"],"catalyst":""},{"name":"High intensity therapies","genericName":"High intensity therapies","slug":"high-intensity-therapies","phase":"phase_3","mechanism":"High intensity therapies refer to aggressive, multi-modal treatment regimens combining chemotherapy, radiation, and/or targeted agents to maximize tumor control.","indications":["Cancer (specific indication not specified in available data)"],"catalyst":""},{"name":"IL2","genericName":"IL2","slug":"il2","phase":"phase_3","mechanism":"IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.","indications":["Metastatic melanoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Low intensity therapies","genericName":"Low intensity therapies","slug":"low-intensity-therapies","phase":"phase_3","mechanism":"Low intensity therapies refer to reduced-dose or less aggressive treatment regimens designed to maintain efficacy while minimizing toxicity in cancer patients.","indications":["Cancer treatment in elderly or frail patients"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":9,"phaseCounts":{"phase_2":3,"phase_3":6},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}